• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在患有子宫乳头状浆液性和透明细胞癌的女性中,最佳减瘤术、肌层浸润深度和年龄是独立的生存预后因素。

Optimal cytoreduction, depth of myometrial invasion, and age are independent prognostic factors for survival in women with uterine papillary serous and clear cell carcinomas.

机构信息

Department of Obstetrics and Gynecology, Tepecik Training and Research Hospital, Izmir, Turkey.

Department of Obstetrics and Gynecology, Tepecik Training and Research Hospital, Izmir, Turkey.

出版信息

Int J Surg. 2016 Aug;32:71-7. doi: 10.1016/j.ijsu.2016.06.041. Epub 2016 Jun 27.

DOI:10.1016/j.ijsu.2016.06.041
PMID:27365052
Abstract

OBJECTIVE

The purpose of this study was to investigate the clinicopathological characteristics, treatment methods, and prognostic factors in women with uterine papillary serous carcinoma (UPSC) and uterine clear-cell carcinoma (UCCC).

STUDY DESIGN

All patients who had undergone surgery for UPCS and UCCC between January 1995 and December 2012 were retrospectively reviewed. Patients with missing data, who did not undergo surgical staging and patients with mixed tumor histology were excluded. Multivariate regression models were used to identify the risk factors for overall survival (OS) and progression-free survival (PFS).

RESULTS

A total of 49 UPSC and 22 UCCC women were included. The majority of the patients were at stage I [IA, 22 (31%) and IB, 18 (25.4%)]. Stages II, III, and IV were identified in 9 (12.7%), 13 (18.3%), and 9 (12.7%) of cases, respectively. Optimal cytoreduction was achieved in 71.8% of cases. Recurrences occurred in 16 patients (22.5%). The 5-year OS rates were 67% for UPSC; 76% for UCCC; 68% for both histology, respectively. Multivariate analysis pointed out that age>67 years (odds ratio (OR): 3.85, p = 0.009 and OR: 3.35, p = 0.014), >50% myometrial invasion (MI) (OR: 2.87, p = 0.037 and OR: 2.46, p = 0.046) and optimal cytoreduction (OR: 3.26, p = 0.006 and OR: 2.77, p = 0.015) were the independent prognostic factors for both PFS and OS.

CONCLUSIONS

Our study demonstrated that optimal cytoreduction, >50% MI, and age >67 years are the most significant factors affecting survival in women with UPSC and UCCC.

摘要

目的

本研究旨在探讨女性子宫乳头状浆液性癌(UPSC)和子宫透明细胞癌(UCCC)的临床病理特征、治疗方法和预后因素。

研究设计

回顾性分析 1995 年 1 月至 2012 年 12 月期间接受 UPSC 和 UCCC 手术治疗的所有患者。排除数据缺失、未行手术分期和混合肿瘤组织学的患者。采用多变量回归模型确定总生存(OS)和无进展生存(PFS)的危险因素。

结果

共纳入 49 例 UPSC 和 22 例 UCCC 患者。大多数患者处于 I 期[IA 期 22 例(31%)和 IB 期 18 例(25.4%)]。II 期、III 期和 IV 期分别为 9 例(12.7%)、13 例(18.3%)和 9 例(12.7%)。71.8%的患者达到了最佳减瘤效果。16 例患者出现复发。UPSC 的 5 年 OS 率为 67%,UCCC 为 76%,两种组织学均为 68%。多因素分析表明,年龄>67 岁(优势比(OR):3.85,p=0.009 和 OR:3.35,p=0.014)、>50%肌层浸润(MI)(OR:2.87,p=0.037 和 OR:2.46,p=0.046)和最佳减瘤效果(OR:3.26,p=0.006 和 OR:2.77,p=0.015)是影响 PFS 和 OS 的独立预后因素。

结论

本研究表明,在 UPSC 和 UCCC 女性中,最佳减瘤效果、>50%MI 和年龄>67 岁是影响生存的最重要因素。

相似文献

1
Optimal cytoreduction, depth of myometrial invasion, and age are independent prognostic factors for survival in women with uterine papillary serous and clear cell carcinomas.在患有子宫乳头状浆液性和透明细胞癌的女性中,最佳减瘤术、肌层浸润深度和年龄是独立的生存预后因素。
Int J Surg. 2016 Aug;32:71-7. doi: 10.1016/j.ijsu.2016.06.041. Epub 2016 Jun 27.
2
Analysis of clinical and pathological characteristics, treatment methods, survival, and prognosis of uterine papillary serous carcinoma.子宫浆液性乳头状癌的临床与病理特征、治疗方法、生存情况及预后分析
Tumori. 2016 Dec 1;102(6):593-599. doi: 10.5301/tj.5000531. Epub 2016 Aug 4.
3
Uterine papillary serous, clear cell, and poorly differentiated endometrioid carcinomas: a comparative study.子宫乳头状浆液性、透明细胞和低分化子宫内膜样癌:一项比较研究。
Int J Gynecol Cancer. 2011 May;21(4):661-7. doi: 10.1097/IGC.0b013e3182150c89.
4
Uterine Papillary Serous Carcinoma: A Single-Institution Review of 62 Cases.子宫浆液性乳头状癌:单机构62例病例回顾
Int J Gynecol Cancer. 2016 Jan;26(1):133-40. doi: 10.1097/IGC.0000000000000569.
5
Is adjuvant therapy necessary for stage IA and IB uterine papillary serous carcinoma and clear cell carcinoma after surgical staging?对于IA期和IB期子宫浆液性乳头状癌及透明细胞癌,手术分期后辅助治疗是否必要?
Int J Gynecol Cancer. 2008 Jul-Aug;18(4):820-4. doi: 10.1111/j.1525-1438.2007.01082.x. Epub 2007 Sep 24.
6
An analysis of current treatment practice in uterine papillary serous and clear cell carcinoma at two high volume cancer centers.两家高容量癌症中心的子宫乳头状浆液性和透明细胞癌当前治疗实践分析。
J Gynecol Oncol. 2015 Jan;26(1):25-31. doi: 10.3802/jgo.2015.26.1.25. Epub 2014 Nov 6.
7
Comparative Survival Outcomes of Uterine Papillary Serous Carcinoma, Clear Cell Carcinoma, Grade 3 Endometrioid Adenocarcinoma, and Carcinosarcoma of Endometrial Cancer in Rajavithi Hospital.拉贾维提医院子宫内膜癌中子宫浆液性乳头状癌、透明细胞癌、3级子宫内膜样腺癌和癌肉瘤的生存结局比较
J Med Assoc Thai. 2016 Feb;99 Suppl 2:S75-83.
8
Prognostic factors and treatment outcomes for patients with surgically staged uterine clear cell carcinoma focusing on the early stage: A Taiwanese Gynecologic Oncology Group study.聚焦早期手术分期的子宫透明细胞癌患者的预后因素和治疗结果:台湾妇癌肿瘤学会研究。
Gynecol Oncol. 2014 Sep;134(3):516-22. doi: 10.1016/j.ygyno.2014.07.005. Epub 2014 Jul 11.
9
Surgical Treatment of Recurrent Endometrial Cancer: Time for a Paradigm Shift.复发性子宫内膜癌的外科治疗:是时候进行范式转变了。
Ann Surg Oncol. 2015 Dec;22(13):4204-10. doi: 10.1245/s10434-015-4504-5. Epub 2015 Mar 17.
10
An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC).早期子宫浆液性乳头状癌(UPSC)的最新临床病理研究
Gynecol Oncol. 2009 Nov;115(2):244-8. doi: 10.1016/j.ygyno.2009.07.030. Epub 2009 Aug 26.

引用本文的文献

1
Construction and validation of nomograms for predicting the prognosis of elderly patients with uterine serous carcinoma: a SEER-based study.基于 SEER 数据库构建并验证预测老年子宫浆液性癌患者预后的列线图模型。
J Cancer Res Clin Oncol. 2023 Nov;149(16):14475-14492. doi: 10.1007/s00432-023-05174-3. Epub 2023 Aug 12.
2
PD-L1 Expression in Endometrial Serous Carcinoma and Its Prognostic Significance.子宫内膜浆液性癌中程序性死亡受体配体1(PD-L1)的表达及其预后意义
Cancer Manag Res. 2021 Dec 14;13:9157-9165. doi: 10.2147/CMAR.S337271. eCollection 2021.
3
Clinicopathological and survival analysis of uterine papillary serous carcinoma: a single institutional review of 106 cases.
子宫浆液性乳头状癌的临床病理与生存分析:106例单机构回顾研究
Cancer Manag Res. 2018 Oct 25;10:4915-4928. doi: 10.2147/CMAR.S179566. eCollection 2018.